Drug Enforcement Administration (DEA) Telemedicine Rules 2027 and Your Clinic’s Plan Before January 1

Drug Enforcement Administration (DEA) Telemedicine Rules 2027

• Your clinic prescribes controlled medications through telemedicine. 
• Some patients have never met their prescribing physician in person. 
• Others receive buprenorphine through video or audio-only appointments.

What should your clinic do before January 1, 2027?

The DEA’s current temporary telemedicine rules are scheduled to expire on December 31, 2026. The government may extend them, replace them with a new registration system, or allow them to expire.

For your clinic, the first task is to find out which prescriptions depend on the temporary rules. The next task is to decide what action each patient may need under the final federal rules.

This guide gives your team a step-by-step process to complete that work.

Step 1: Find out which prescribing rules your clinic currently uses

Before reviewing patient records, identify the federal rule that allows each type of telemedicine prescription.

There are three separate pathways your team should know about.

Prescribing pathway	What it currently allows	Prescribing pathway
Temporary telemedicine flexibility	Eligible DEA-registered practitioners can prescribe Schedule II to V controlled substances through audio-video telemedicine without a prior in-person medical evaluation.	Temporary telemedicine flexibility
Separate buprenorphine rule	Eligible practitioners can prescribe FDA-approved Schedule III to V medications for opioid use disorder through audio-video or audio-only telemedicine.	Separate buprenorphine rule
Ryan Haight Act and its exceptions	The general federal rule requires an in-person medical evaluation before remote prescribing of controlled substances, subject to specific exceptions.	Ryan Haight Act and its exceptions

The fourth temporary extension explains the current Schedule II-V pathway. The separate buprenorphine rule, together with its later effective-date change, explains the OUD pathway.

Your task: Ask your compliance officer to identify which pathway each prescribing department uses. For example, the process used by an addiction treatment department may differ from the process used by a psychiatry department prescribing other controlled medications.

Do not start by asking every physician to change their workflow. First establish which legal pathway supports each type of prescription.

Step 2: Create a list of patients who receive controlled medications through telemedicine

Now ask your EHR administrator or prescribing team to prepare a report of patients who received controlled-substance prescriptions through telemedicine.

Include these fields:

Information to collect	Why you need it
Patient name and medical record number	To identify the correct patient.
Prescribing practitioner’s name	The in-person evaluation history must be checked for the relevant practitioner-patient relationship.
Medication name	To identify the prescription being reviewed.

Do not assume that every prescription in the report is affected by the December 31 deadline. The purpose of this report is to separate prescriptions that depend on the temporary flexibility from those that may have another legal basis.

Once the report is ready, the next step is to review each patient individually.

Step 3: Sort patients into the correct review groups

The clinic should use the following groups to decide which records need further review.

Group A: Patients who have had an in-person evaluation with their prescribing practitioner

Check the patient’s record for an in-person medical evaluation conducted by the practitioner who currently prescribes the controlled medication.

Under the Ryan Haight Act explanation in the DEA’s fourth extension, once that practitioner has conducted at least one in-person medical evaluation during the practitioner-patient relationship, the Act’s specific in-person requirement for remote prescribing no longer applies to that relationship.

Record to keep: The date of the examination, the practitioner who conducted it, and the location where it took place.

Group B: Patients who have never had an in-person evaluation with their prescribing practitioner

These patients need a closer review.

If the temporary rule expires without another applicable pathway, the clinic may need to arrange an in-person evaluation or establish another permitted prescribing arrangement.

Record to keep: The patient’s current treatment, the prescribing practitioner, the medication, and the legal pathway currently being used.

Group C: Patients receiving buprenorphine for opioid use disorder

Review these patients separately because the buprenorphine rule provides its own telemedicine pathway.

Check:

• The date of the first prescription under this rule.
• Whether the practitioner reviewed the patient’s state PDMP.
• Whether the review date and time are recorded.
• Whether the patient’s initial six-month prescribing period has ended or is approaching its end.

The rule permits an initial six-month supply, which may be issued through multiple prescriptions as medically appropriate. After that period, the practitioner must use another permitted pathway or conduct an in-person medical evaluation.

The final rule sets out these requirements.

Group D: Patients whose prescriptions may fall under another legal exception

Do not automatically place every patient who has never had an in-person evaluation into the same category.

The Ryan Haight Act contains specific exceptions. Certain federal programs and other qualifying circumstances may have separate rules.

Ask your compliance officer or legal counsel to review these cases. Record the exact exception being used and the rule that supports it.

At the end of this step, your clinic should have a patient list with a clear review category and a named person responsible for resolving any uncertain cases.

Step 4: Check whether your clinic and practitioners are authorized to prescribe

Patient records are only one part of the review. Your clinic must also check the practitioners who issue the prescriptions.

Ask your compliance officer to verify the following for each prescribing practitioner:

1. DEA registration: Is the practitioner’s DEA registration active?
2. Medication schedule: Does the registration authorize the practitioner to prescribe the relevant controlled-substance schedule?
3. State authorization: Is the practitioner licensed or otherwise authorized to treat patients in the states where those patients are located?
4. State prescribing rules: Are there additional state requirements for the medication or telemedicine encounter?
5. Practice arrangements: Does the practitioner’s current employment or platform arrangement allow them to provide the service?

Keep the verification date and the source used for each check.

A federal telemedicine permission does not automatically provide a state medical license or remove state prescribing requirements. Your team must check both levels.

Step 5: Prepare for the DEA’s January 2027 decision

As of October 30, 2026, the DEA’s final special registration rule is still pending review at OIRA. The agency submitted it on August 25, 2026, under RIN 1117-AB40.

You can check its status through the OIRA review search.

Your clinic should prepare for each of the following outcomes.

Scenario 1: The DEA issues another temporary extension

What to do:

1. Download the new rule from the Federal Register.
2. Check the new expiration date.
3. Confirm which medication schedules and encounter types it covers.
4. Identify any new conditions.
5. Ask the compliance officer to compare the new rule with the clinic’s current procedures.
6. Give the updated instructions to prescribing practitioners.

Do not assume that a new extension will have exactly the same conditions as the current one.

Scenario 2: The final special registration rule takes effect

The DEA’s proposed framework includes three registration categories:

• Telemedicine Prescribing Registration.
• Advanced Telemedicine Prescribing Registration.
• Telemedicine Platform Registration.

These categories are part of the proposal. The final rule may change them.

What to do:

1. Download the final rule.
2. Check which practitioners and platforms qualify.
3. Identify the registration category that may apply to your organization.
4. Review the final application process, fees, state requirements, and effective date.
5. Ask legal counsel to confirm whether your organization qualifies.
6. Do not begin using the new pathway until the required registration and other conditions are satisfied.

A published final rule does not necessarily mean every organization can start using the new pathway immediately. Check its effective date and any implementation periods.

Scenario 3: The temporary rule expires without another rule taking effect

What to do:

1. Stop using the expired temporary permission as the basis for new prescriptions.
2. Review the patient groups identified in Step 3.
3. Check whether another federal exception or prescribing pathway applies to each patient.
4. Arrange in-person evaluations where legally required.
5. Have the prescribing practitioner review each patient’s treatment plan.
6. Update the clinic’s prescribing procedures before issuing prescriptions under the new legal position.

Do not make a blanket decision to stop every telemedicine prescription. The legal pathway may differ by patient and medication.

Step 6: Prepare your EHR and patient records for the change

Your EHR should help the clinic answer three questions quickly:

• Which practitioner issued the prescription?
• Which legal pathway supported it?
• What evidence in the record supports that pathway?

Ask your EHR administrator to test whether the system can:

EHR function	What the system should allow your team to do
Patient history	Find the date and details of an in-person medical evaluation.
Prescription history	View the medication, schedule, quantity, prescriber, and prescription date.
Encounter records	Identify the type of telemedicine appointment and the patient’s location.
PDMP documentation	Record the review date and time for prescriptions covered by the buprenorphine rule.
Reporting	Generate a list of patients whose prescriptions rely on the temporary flexibility.
Audit trail	Identify who updated a record or prescribing procedure and when.

If the EHR cannot produce the required report, create a temporary spreadsheet or manual review process. Assign one person to maintain it and check that the information matches the patient’s medical record.

Do not wait until the last week of December to discover that your system cannot identify the patients who may be affected.

Step 7: Prepare appointment and patient communication procedures

Once the patient review is complete, the practice manager should work with the medical director to estimate how many patients may need an in-person appointment.

Check:

• How many patients are in the affected group?
• Which patients need clinical review first?
• How many in-person appointments can the clinic offer each week?
• Do patients need to travel to another clinic location?
• Which patients need to be contacted about a possible change in their treatment arrangements?

Prepare a message for affected patients, but send it only after the clinic confirms which rule applies.

For example:

Subject: Update about your telemedicine appointments

Our clinic is reviewing upcoming federal changes to the rules for prescribing certain controlled medications through telemedicine.

Depending on the final rules and your treatment history, you may need an in-person appointment or a different care arrangement. Our team will contact you if a change applies to your care.

Please contact our office if you have questions about your current treatment or upcoming appointments.

Do not tell patients that all telemedicine prescriptions will stop on January 1. The outcome will depend on the final federal rules and the legal pathway available for each patient.

Step 8: Complete this final review before issuing prescriptions in 2027

Before the clinic starts its January 2027 prescribing workflow, the compliance officer and medical director should complete this review.

Final check	Responsible person	Complete
Confirm the latest DEA rule and its effective date.	Compliance officer	Yes
Confirm which prescribing pathway applies to each service.	Compliance officer	Yes
Review patients who may need an in-person evaluation.	Medical director	Yes
Check practitioner DEA registrations and state authorizations.	Compliance officer	Yes
Confirm EHR reports and documentation processes are working.	EHR administrator	Yes
Update prescribing procedures and staff instructions.	Medical director	Yes
Contact patients whose care arrangements need to change.	Practice manager	Yes
Document approval of the updated workflow.	Medical director and compliance officer	Yes

Do not mark the review complete simply because the clinic has read the new rule. The patient records, practitioner authorizations, EHR workflow, and staff instructions must all reflect the legal requirements that apply from the effective date.

Official sources to use during your review

Use the original government documents when confirming a rule or updating a clinic procedure.

• Fourth DEA telemedicine extension: Current temporary flexibilities through December 31, 2026.
• Buprenorphine telemedicine rule: Separate prescribing pathway for qualifying OUD treatment.
• OIRA review records: Search for RIN 1117-AB40 to check the special registration rule.
• DEA: Official controlled-substance prescribing announcements.
• HHS telehealth guidance: Federal telehealth prescribing information.

Important: This guide reflects federal information available on October 30, 2026. It is an operational guide, not legal advice. Have your compliance officer or healthcare attorney confirm the final rules and state requirements before changing prescribing procedures.